The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J01 | Antibacterials for systemic use | |
3 | J01M | Quinolone antibacterials | |
4 | J01MA | Fluoroquinolones |
Code | Title | |
---|---|---|
J01MA01 | Ofloxacin | |
J01MA02 | Ciprofloxacin | |
J01MA03 | Pefloxacin | |
J01MA04 | Enoxacin | |
J01MA05 | Temafloxacin | |
J01MA06 | Norfloxacin | |
J01MA07 | Lomefloxacin | |
J01MA08 | Fleroxacin | |
J01MA09 | Sparfloxacin | |
J01MA10 | Rufloxacin | |
J01MA11 | Grepafloxacin | |
J01MA12 | Levofloxacin | |
J01MA13 | Trovafloxacin | |
J01MA14 | Moxifloxacin | |
J01MA15 | Gemifloxacin | |
J01MA16 | Gatifloxacin | |
J01MA17 | Prulifloxacin | |
J01MA18 | Pazufloxacin | |
J01MA19 | Garenoxacin | |
J01MA21 | ||
J01MA22 | ||
J01MA23 | ||
J01MA24 | ||
J01MA25 |
Active Ingredient | Description | |
---|---|---|
Ciprofloxacin |
Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination. |
|
Delafloxacin |
Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination. |
|
Gatifloxacin |
Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. |
|
Lascufloxacin |
|
|
Levofloxacin |
Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class. As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA – DNA-gyrase complex and topoisomerase IV. |
|
Lomefloxacin |
Lomefloxacin is a synthetic broad-spectrum antimicrobial agent for oral administration. Lomefloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. |
|
Moxifloxacin |
Moxifloxacin, a fourth-generation fluoroquinolone, has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens. The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. |
|
Nadifloxacin |
|
|
Norfloxacin |
Norfloxacin has a rapid bactericidal action and inhibits synthesis of bacterial deoxyribonucleic acid (DNA). Norfloxacin has a broad spectrum of antibacterial activity against gram-positive and gram-negative aerobic bacteria. |
|
Ofloxacin |
Ofloxacin is a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both Gram-negative and Gram-positive organisms. The primary mode of action of the quinolones is the specific inhibition of bacterial DNA gyrase. This enzyme is required for DNA replication, transcription, repair and recombination. |
|
Pefloxacin |
Pefloxacin is a fluoroquinolone antibiotic with broad-spectrum antimicrobial activity. Pefloxacin inhibits the activity of microbial DNA gyrase and topoisomerase IV. This disrupts DNA replication and prevents cell division. |
|
Prulifloxacin |
Prulifloxacin is a wide spectrum antibacterial agents belonging to the fluoroquinolone group and provided with high efficacy. Prulifloxacin exerts its antibacterial activity by the selective inhibition of the DNA-gyrase, an essential enzyme present in bacteria and involved in duplication, transcription and repair of DNA. |
|
Sitafloxacin |
|
|
Tosufloxacin |
|
Title | Information Source | Document Type | |
---|---|---|---|
AMESOL Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
AVELOX Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
AVELOX Solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CIPLOX Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
CIPRO Film-coated tablet / Oral suspension kit | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
Ciproxin Tablets 250mg | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ERELAN Film-coated tablet | MPI, EU: SmPC | ||
FACTIVE Tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
GYRABLOCK Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
LEVAQUIN Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
MEDOCIPRIN Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
MEDOFLOXINE Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
OFLOXIN Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
PROFLOXIN Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
QUINSAIR Nebuliser solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
QUOFENIX Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
QUOFENIX Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
TARIVID Solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TAVANIC Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
VIPROLOX Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |